# A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

> **NCT01075282** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 810 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Glargine
- **DRUG:** LY2189265
- **DRUG:** Metformin
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01075282
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-05
- **Final completion:** 2012-11
- **Target enrollment:** 810 (ACTUAL)
- **Last updated:** 2015-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01075282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01075282, "A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01075282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*